Gilead expands its big bet on Arcus, moving into inflammation in large new collaboration
Gilead and Arcus are expanding their already significant partnership, adding inflammation targets to what was already one of the biggest collaboration deals in the biotech world.
In 2020, the companies announced a 10-year agreement to go after cancer targets that came with a $175 million upfront, a $200 million equity investment and as much as $1.6 billion in milestone payments. That deal made Gilead a development and commercial partner on Arcus’s programs, including its closely-watched TIGIT candidate, with an option to pay $150 million per molecule for future candidates.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.